Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olezarsen in severe hypertriglyceridemia
NCT05681351Phase 3Active, not recruiting
- Sponsor
- Ionis Pharmaceuticals
- Start
- Dec 2022
- Primary completion
- Mar 2027
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 33
01
Overview
Phase 3, open-label, single-arm trial of olezarsen in hypertriglyceridemia, sponsored by Ionis Pharmaceuticals. Primary endpoints: Change in Clinical Laboratory Values at 157 weeks, Adverse Events at 157 weeks and 1 more. Started Dec 2022; status: active, not recruiting.
02
Drugs
olezarsen
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT05681351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05681351.